Together with the development of new therapeutic agents, innovation in the delivery system of anti-tumor drugs is required to increase tumor-specificity and avoid unexpected toxicity. To achieve higher efficiency, we combined a live cell-mediated drug delivery system with nanotechnology, with the aim to prove that blood monocytes can be a cargo to deliver antitumor drugs encapsulated in Polymeric poly(D, L-lactide-co-glycolide) acid based nanoparticles (PLGA NPs). In this study, we have characterized how isolated purified monocytes efficiently internalize PLGA-NPs and have imaged in vivo their trafficking upon intravenous injection in tumor-bearing mice. Monocytes carrying PLGA-Cy7 NPs were able to reach the tumor site, with superior efficiency than free PLGA-Cy7 NPs, and the bio-distribution analysis confirmed that tumors were the most reached among peripheral tissues. We further demonstrate that monocytes carrying Doxorubicin encapsulated PLGA NPs (PLGA-Doxo) induced strong killing of co-cultured tumor cells. Our studies provide proof-of-concept evidence that monocytes can be exploited in approaches of live cell-mediated drug delivery systems for tumor therapy.

Allavena, P., Palmioli, A., Avigni, R., Sironi, M., La Ferla, B., Maeda, A. (2020). PLGA Based Nanoparticles for the Monocyte-Mediated Anti-Tumor Drug Delivery System. JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 16(2), 212-223 [10.1166/jbn.2020.2881].

PLGA Based Nanoparticles for the Monocyte-Mediated Anti-Tumor Drug Delivery System

Palmioli, A;La Ferla, B
Co-ultimo
;
2020

Abstract

Together with the development of new therapeutic agents, innovation in the delivery system of anti-tumor drugs is required to increase tumor-specificity and avoid unexpected toxicity. To achieve higher efficiency, we combined a live cell-mediated drug delivery system with nanotechnology, with the aim to prove that blood monocytes can be a cargo to deliver antitumor drugs encapsulated in Polymeric poly(D, L-lactide-co-glycolide) acid based nanoparticles (PLGA NPs). In this study, we have characterized how isolated purified monocytes efficiently internalize PLGA-NPs and have imaged in vivo their trafficking upon intravenous injection in tumor-bearing mice. Monocytes carrying PLGA-Cy7 NPs were able to reach the tumor site, with superior efficiency than free PLGA-Cy7 NPs, and the bio-distribution analysis confirmed that tumors were the most reached among peripheral tissues. We further demonstrate that monocytes carrying Doxorubicin encapsulated PLGA NPs (PLGA-Doxo) induced strong killing of co-cultured tumor cells. Our studies provide proof-of-concept evidence that monocytes can be exploited in approaches of live cell-mediated drug delivery systems for tumor therapy.
Articolo in rivista - Articolo scientifico
DOXORUBICIN; LIVE CELL-MEDIATED DRUG DELIVERY; MONOCYTES; PLGA NPs; TUMOR
English
2020
16
2
212
223
none
Allavena, P., Palmioli, A., Avigni, R., Sironi, M., La Ferla, B., Maeda, A. (2020). PLGA Based Nanoparticles for the Monocyte-Mediated Anti-Tumor Drug Delivery System. JOURNAL OF BIOMEDICAL NANOTECHNOLOGY, 16(2), 212-223 [10.1166/jbn.2020.2881].
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/267372
Citazioni
  • Scopus 32
  • ???jsp.display-item.citation.isi??? 28
Social impact